// App-Quantinova.ai

S129 : ACUTE RESISTANCE TO BET INHIBITORS REMODELS COMPENSATORY TRANSCRIPTIONAL PROGRAMMES VIA P300 CO-ACTIVATION

Researchers

Presenter

  • Daniel Sasca

Principal Investigators

  • Hikari Osaki

  • George Giotopoulos

  • Eshwar Meduri

  • Viral Shah

  • Markus Meyerhfer

  • Benedict Schubert

  • Haiyang Yun

  • Sarah J Horton

  • Shuchi Agrawal-Singh

  • Faisal Basheer

  • Michael W Khn

  • Borhane Guezguez

  • Matthias Theobald

  • Thomas Kindler

  • Paolo Gallipoli

  • Rab K Prinjha

  • Brian JP Huntly

Medical Centers

  • German Consortium for Translational Cancer Research,Berlin,Germany

  • Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Cancer Center,University Medical Center Mainz,Mainz,Germany

  • Department of Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany

  • German Cancer Research Centre, Heidelberg, Germany

  • Adaptive Immunity and Immuno-epigenetics Research Unit,GlaxoSmithKline Pharma,Stevenage,United Kingdom

  • Third Department of Medicine (Hematology, Oncology and Pneumology),University Medical Center Mainz,Mainz,Germany

  • Department of Oncology, University of Cambridge, Cambridge, United Kingdom

  • Wellcome Trust-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom

Locations

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • DMSO

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved